Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 23, 2019
- Accepted December 9, 2019
- First Published February 12, 2020.
Article Versions
- Previous version (February 12, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Carrie M. Hersh, DO,
- Haleigh Harris, BA,
- Devon Conway, MD and
- Le H. Hua, MD
- Carrie M. Hersh, DO,
(1) Commercial, Biogen Idec, US Medical MS Franchise Advisory Board (2) Commercial, TEVA, MS Next Generation Advisory Board (3) Commercial, Genentech, US Medical MS Franchise Advisory Board (4) Commercial, Novartis, Siponimod Advisory Board (5) Commercial, EMD Serono, Curious About MS Advisory Board
NONE
(1) Commercial, Genzyme, speaker/consulting honoraria (2) Commercial, Novartis, speaker/consulting honoraria (3) Commercial, Biogen, speaker/consulting honoraria (4) Commercial, Genentech, speaker/consulting honoraria (5) Commercial, EMD Serono, speaker/consulting honoraria
NONE
NONE
NONE
NONE
(1) Commercial, Genzyme, speaker/consulting honoraria (2) Commercial, Novartis, speaker/consulting honoraria (3) Commercial, Biogen, speaker/consulting honoraria (4) Commercial, Genentech, speaker/consulting honoraria (5) Commercial, EMD Serono, speaker/consulting honoraria
(1) Commercial, Genzyme, speakers' bureau (2) Commercial, Novartis, speakers' bureau (3) Commercial, Biogen, speakers' bureau
NONE
NONE
(1) Commercial, Biogen (2) Commercial, Genentech (3) Commercial, PCORI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Haleigh Harris, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Devon Conway, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have served as a consultant for Novartis Pharmaceuticals and Tanabe Laboratories.
NONE
NONE
NONE
(1) Novartis Pharmaceuticals
NONE
NONE
(1) National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Le H. Hua, MD
(1) Biogen (2) EMD Serono (3) Novartis
NONE
(1) Biogen, speaker honoraria, funding for travel (2) EMD Serono, speaker honoraria, funding for travel (3) Novartis, speaker honoraria, funding for travel (4) Genzyme, speaker honoraria, funding for travel
NONE
NONE
NONE
NONE
(1) Novartis (2) EMD Serono (3) Biogen (4) Genzyme (5) Genentech (6) Celgene (7) TG Therapeutics
(1) Genzyme (2) Biogen (3) Novartis (4) EMD Serono
NONE
NONE
NONE
NONE
NONE
Eric and Sheila Samson Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Lou Ruvo Center for Brain Health (CMH, HH, LHH), Cleveland Clinic, Las Vegas, NV; and Mellen Center for Multiple Sclerosis Treatment and Research (DC), Cleveland Clinic, Cleveland, OH.
- Correspondence
Carrie M. Hersh hershc{at}ccf.org
Article usage
The Nerve!: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.